End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
58.7 TWD | 0.00% | +0.17% | -15.42% |
Business Summary
Sales per Business
TWD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
CDMO
95.1
%
| 3 | 57.5 % | 40 | 95.1 % | +1,358.80% |
New Anticancer Drug
4.9
%
| 2 | 42.5 % | 2 | 4.9 % | +1.40% |
Sales per region
TWD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Taiwan
96.2
%
| 3 | 72.9 % | 40 | 96.2 % | +1,065.18% |
Others
3.8
%
| 1 | 27.1 % | 2 | 3.8 % | +21.97% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Heidi Wang
CEO | Chief Executive Officer | - | 23-06-01 |
Chih Chuan Chen
DFI | Director of Finance/CFO | - | - |
Kuo Lin Kao
AUD | Comptroller/Controller/Auditor | - | 17-10-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ta Meng Tseng
BRD | Director/Board Member | 66 | 13-02-06 |
Chih Chuan Chen
DFI | Director of Finance/CFO | - | - |
Tai Chang Wang
BRD | Director/Board Member | 65 | - |
Lung Yeh Cho
BRD | Director/Board Member | - | 13-02-06 |
Chen Yue Feng
BRD | Director/Board Member | - | - |
Chung Ming Chang
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 229,439,000 | 151,802,374 ( 66.16 %) | 191,000 ( 0.0832 %) | 66.16 % |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-15.42% | 416M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+38.11% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- 4174 Stock
- Company OBI Pharma, Inc.